Advances in Cancer Immunotherapy™ – Tampa, Fla.

Saturday, Nov. 21, 2020
8:00 a.m. EST 

Organizers:
Christina Bachmeier, PharmD, BCOP – Moffitt Cancer Center
Marco L. Davila, MD – Moffitt Cancer Center
Jose Lutzky, MD, FACP – University of Miami Sylvester Cancer Center


ACI Tampa

This program has already taken place.

Program Agenda

Nov. 21, 2020 Program

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE-, CNE-, MOC-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, at the conclusion of this activity, participants of this should be able to:

• Describe the rationale for common approaches to cancer immunotherapy.
• Identify the appropriate clinical management of immune-related adverse events of immunotherapy agents.
• Implement cancer immunotherapy treatments for skin cancers, lung, genitourinary, head and neck,  hematologic cancers, and/or additional solid tumors into clinical practice appropriately.
• Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.

Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.

View the SITC Meeting Code of Conduct.

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

The 2019–2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.

Participation in these CME-, CPE-, CNE- and MOC-certified online pre-program courses by ACI program attendees is strongly recommended. 

• Basic Immunology Concepts
  This course covers some of the key immunology needed to understand the ACI program. Basic Immunology Concepts is also the first module in the Certificate in Cancer Immunotherapy program, produced by SITC. ACI registrants will receive a discount code to use when registering for the Basic Immunology Concepts course. 

• Mechanisms of Immune-related Adverse Events 
  This interactive course provides an overview of the mechanisms by which cancer immunotherapy may activate immune-related adverse events (irAEs), which is critical to understanding how and why immune-related adverse events occur and how they can be treated.